Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis
| Autor: | Catherine M. Dalton, E T Lim, Gavin Giovannoni, Geoffrey Keir, E. J. Thompson, Markus Reindl, David Miller, Thomas Berger, K Fernando |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Pathology medicine.medical_specialty Multiple Sclerosis Poser criteria Myelin oligodendrocyte glycoprotein 03 medical and health sciences Myelin 0302 clinical medicine Reference Values medicine Humans Optic neuritis 030212 general & internal medicine Autoantibodies Clinically isolated syndrome biology business.industry Multiple sclerosis Reproducibility of Results medicine.disease Oligodendrocyte medicine.anatomical_structure Neurology Immunology biology.protein Female Neurology (clinical) Antibody business Biomarkers Myelin Proteins 030217 neurology & neurosurgery |
| Zdroj: | Multiple Sclerosis Journal. 11:492-494 |
| ISSN: | 1477-0970 1352-4585 |
| Popis: | This study investigates whether the presence of serum and plasma anti-myelin oligodendrocyte glycoprotein (MOG) and anti-myelin basic protein (MBP) in patients presenting with a clinically isolated syndrome compatible with demyelination (CIS) predicts early conversion to multiple sclerosis (MS). Forty-seven patients with CIS (46 with optic neuritis) had anti-MOG and anti-MBP antibodies analysed at baseline, and clinical and magnetic resonance imaging assessments. There was no evidence that the MS status based on either the McDonald or Poser criteria relates to the antibody status. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|